Destiny Pharma plc (DEST.L)
- Previous Close
16.75 - Open
16.75 - Bid 15.50 x --
- Ask 16.50 x --
- Day's Range
14.67 - 17.00 - 52 Week Range
13.19 - 84.00 - Volume
1,536,814 - Avg. Volume
587,087 - Market Cap (intraday)
15.488M - Beta (5Y Monthly) 0.24
- PE Ratio (TTM)
-- - EPS (TTM)
-0.06 - Earnings Date Apr 25, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
61.00
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, dermal, oral and ocular infections. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; Sebela Pharmaceuticals; the University of Southampton; Aston University; the University of Sheffield; National Biofilms Innovation Centre; National Institute of Allergy and Infectious Diseases; Cystic Fibrosis Foundation; Cardiff University; and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.
www.destinypharma.comRecent News: DEST.L
Performance Overview: DEST.L
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DEST.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DEST.L
Valuation Measures
Market Cap
15.49M
Enterprise Value
9.11M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.69
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.35
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-44.90%
Return on Equity (ttm)
-67.29%
Revenue (ttm)
831.55k
Net Income Avi to Common (ttm)
-5.66M
Diluted EPS (ttm)
-0.06
Balance Sheet and Cash Flow
Total Cash (mrq)
6.38M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-3.82M
Research Analysis: DEST.L
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: DEST.L
DEST.L does not have Company Insights